(NASDAQ: PVLA) Palvella Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 70.58%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.49%.
Palvella Therapeutics's earnings in 2026 is -$35,066,000.On average, 17 Wall Street analysts forecast PVLA's earnings for 2026 to be -$46,792,012, with the lowest PVLA earnings forecast at -$57,070,820, and the highest PVLA earnings forecast at -$36,539,245. On average, 15 Wall Street analysts forecast PVLA's earnings for 2027 to be -$70,661,478, with the lowest PVLA earnings forecast at -$116,693,588, and the highest PVLA earnings forecast at -$39,894,890.
In 2028, PVLA is forecast to generate -$37,411,594 in earnings, with the lowest earnings forecast at -$128,989,333 and the highest earnings forecast at $8,699,820.